Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders

Patent No. EP3716992 (titled "Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders") was filed by Regeneron Pharmaceuticals on Nov 29, 2018. The application was issued on Aug 10, 2022.

Patent Summary

224> The present invention provides a VEGF antagonist for use in methods for treating or preventing diabetic retinopathy in a patient in need of such treatment or prevention, wherein said patient does not suffer from center involved diabetic macular edema, said method comprising administering, to an eye of the patient, 5 monthly doses followed by one or more secondary doses every 8 weeks of about 2 mg of VEGF antagonist that is a VEGF receptor-based chimeric molecule comprising (1) an immunoglobin-like (Ig) domain 2 of a VEGFR1 and (2) Ig domain 3 of VEGFR2, and (3) a multimerizing component.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3716992

REGENERON PHARMACEUTICALS
Application Number
EP18825837A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Jul 8, 2022
Publication Date
Aug 10, 2022